Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
Identifieur interne : 001378 ( Ncbi/Curation ); précédent : 001377; suivant : 001379Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
Auteurs : Raymond H. See [Canada] ; Alexander N. Zakhartchouk ; Martin Petric ; David J. Lawrence ; Catherine P Y. Mok ; Robert J. Hogan ; Thomas Rowe ; Lois A. Zitzow ; Karuna P. Karunakaran ; Mary M. Hitt ; Frank L. Graham ; Ludvik Prevec ; James B. Mahony ; Chetna Sharon ; Thierry C. Auperin ; James M. Rini ; Aubrey J. Tingle ; David W. Scheifele ; Danuta M. Skowronski ; David M. Patrick ; Thomas G. Voss ; Lorne A. Babiuk ; Jack Gauldie ; Rachel L. Roper ; Robert C. Brunham ; B Brett FinlaySource :
- The Journal of general virology [ 0022-1317 ] ; 2006.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Immunoglobuline A (immunologie), Immunoglobuline A (sang), Injections musculaires, Injections sous-cutanées, Modèles animaux de maladie humaine, Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines nucléocapside (génétique), Souris, Spécificité des anticorps, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Tests de neutralisation, Vaccination, Vaccins antiviraux (administration et posologie), Vaccins à ADN (administration et posologie), Vaccins à ADN (génétique), Virus du SRAS (), Virus du SRAS (immunologie), Évaluation préclinique de médicament.
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins à ADN.
- génétique : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines nucléocapside, Vaccins à ADN.
- immunologie : Anticorps antiviraux, Glycoprotéines membranaires, Immunoglobuline A, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Virus du SRAS.
- sang : Anticorps antiviraux, Immunoglobuline A.
- Administration par voie nasale, Animaux, Femelle, Glycoprotéine de spicule des coronavirus, Injections musculaires, Injections sous-cutanées, Modèles animaux de maladie humaine, Souris, Spécificité des anticorps, Syndrome respiratoire aigu sévère, Tests de neutralisation, Vaccination, Virus du SRAS, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Specificity, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Immunoglobulin A (blood), Immunoglobulin A (immunology), Injections, Intramuscular, Injections, Subcutaneous, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Neutralization Tests, Nucleocapsid Proteins (genetics), SARS Virus (chemistry), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccination, Vaccines, DNA (administration & dosage), Vaccines, DNA (genetics), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage).
- MESH :
- chemical , administration & dosage : Vaccines, DNA, Viral Vaccines.
- chemical , blood : Antibodies, Viral, Immunoglobulin A.
- chemical , genetics : Membrane Glycoproteins, Nucleocapsid Proteins, Vaccines, DNA, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral, Immunoglobulin A, Membrane Glycoproteins, Viral Envelope Proteins.
- chemistry : SARS Virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Antibody Specificity, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Injections, Intramuscular, Injections, Subcutaneous, Mice, Neutralization Tests, Spike Glycoprotein, Coronavirus, Vaccination.
Abstract
Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.
DOI: 10.1099/vir.0.81579-0
PubMed: 16476986
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002344
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002344
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002257
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001378
Links to Exploration step
pubmed:16476986Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.</title>
<author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H" last="See">Raymond H. See</name>
<affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea>
<wicri:noRegion>BC V5Z 4R4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zakhartchouk, Alexander N" sort="Zakhartchouk, Alexander N" uniqKey="Zakhartchouk A" first="Alexander N" last="Zakhartchouk">Alexander N. Zakhartchouk</name>
</author>
<author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name>
</author>
<author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J" last="Lawrence">David J. Lawrence</name>
</author>
<author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P Y" last="Mok">Catherine P Y. Mok</name>
</author>
<author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name>
</author>
<author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name>
</author>
<author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A" last="Zitzow">Lois A. Zitzow</name>
</author>
<author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P" last="Karunakaran">Karuna P. Karunakaran</name>
</author>
<author><name sortKey="Hitt, Mary M" sort="Hitt, Mary M" uniqKey="Hitt M" first="Mary M" last="Hitt">Mary M. Hitt</name>
</author>
<author><name sortKey="Graham, Frank L" sort="Graham, Frank L" uniqKey="Graham F" first="Frank L" last="Graham">Frank L. Graham</name>
</author>
<author><name sortKey="Prevec, Ludvik" sort="Prevec, Ludvik" uniqKey="Prevec L" first="Ludvik" last="Prevec">Ludvik Prevec</name>
</author>
<author><name sortKey="Mahony, James B" sort="Mahony, James B" uniqKey="Mahony J" first="James B" last="Mahony">James B. Mahony</name>
</author>
<author><name sortKey="Sharon, Chetna" sort="Sharon, Chetna" uniqKey="Sharon C" first="Chetna" last="Sharon">Chetna Sharon</name>
</author>
<author><name sortKey="Auperin, Thierry C" sort="Auperin, Thierry C" uniqKey="Auperin T" first="Thierry C" last="Auperin">Thierry C. Auperin</name>
</author>
<author><name sortKey="Rini, James M" sort="Rini, James M" uniqKey="Rini J" first="James M" last="Rini">James M. Rini</name>
</author>
<author><name sortKey="Tingle, Aubrey J" sort="Tingle, Aubrey J" uniqKey="Tingle A" first="Aubrey J" last="Tingle">Aubrey J. Tingle</name>
</author>
<author><name sortKey="Scheifele, David W" sort="Scheifele, David W" uniqKey="Scheifele D" first="David W" last="Scheifele">David W. Scheifele</name>
</author>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
</author>
<author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M" last="Patrick">David M. Patrick</name>
</author>
<author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G" last="Voss">Thomas G. Voss</name>
</author>
<author><name sortKey="Babiuk, Lorne A" sort="Babiuk, Lorne A" uniqKey="Babiuk L" first="Lorne A" last="Babiuk">Lorne A. Babiuk</name>
</author>
<author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name>
</author>
<author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L" last="Roper">Rachel L. Roper</name>
</author>
<author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C" last="Brunham">Robert C. Brunham</name>
</author>
<author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B Brett" last="Finlay">B Brett Finlay</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16476986</idno>
<idno type="pmid">16476986</idno>
<idno type="doi">10.1099/vir.0.81579-0</idno>
<idno type="wicri:Area/PubMed/Corpus">002344</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002344</idno>
<idno type="wicri:Area/PubMed/Curation">002344</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002344</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002257</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002257</idno>
<idno type="wicri:Area/Ncbi/Merge">001378</idno>
<idno type="wicri:Area/Ncbi/Curation">001378</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.</title>
<author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H" last="See">Raymond H. See</name>
<affiliation wicri:level="1"><nlm:affiliation>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4</wicri:regionArea>
<wicri:noRegion>BC V5Z 4R4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zakhartchouk, Alexander N" sort="Zakhartchouk, Alexander N" uniqKey="Zakhartchouk A" first="Alexander N" last="Zakhartchouk">Alexander N. Zakhartchouk</name>
</author>
<author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name>
</author>
<author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J" last="Lawrence">David J. Lawrence</name>
</author>
<author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P Y" last="Mok">Catherine P Y. Mok</name>
</author>
<author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name>
</author>
<author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name>
</author>
<author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A" last="Zitzow">Lois A. Zitzow</name>
</author>
<author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P" last="Karunakaran">Karuna P. Karunakaran</name>
</author>
<author><name sortKey="Hitt, Mary M" sort="Hitt, Mary M" uniqKey="Hitt M" first="Mary M" last="Hitt">Mary M. Hitt</name>
</author>
<author><name sortKey="Graham, Frank L" sort="Graham, Frank L" uniqKey="Graham F" first="Frank L" last="Graham">Frank L. Graham</name>
</author>
<author><name sortKey="Prevec, Ludvik" sort="Prevec, Ludvik" uniqKey="Prevec L" first="Ludvik" last="Prevec">Ludvik Prevec</name>
</author>
<author><name sortKey="Mahony, James B" sort="Mahony, James B" uniqKey="Mahony J" first="James B" last="Mahony">James B. Mahony</name>
</author>
<author><name sortKey="Sharon, Chetna" sort="Sharon, Chetna" uniqKey="Sharon C" first="Chetna" last="Sharon">Chetna Sharon</name>
</author>
<author><name sortKey="Auperin, Thierry C" sort="Auperin, Thierry C" uniqKey="Auperin T" first="Thierry C" last="Auperin">Thierry C. Auperin</name>
</author>
<author><name sortKey="Rini, James M" sort="Rini, James M" uniqKey="Rini J" first="James M" last="Rini">James M. Rini</name>
</author>
<author><name sortKey="Tingle, Aubrey J" sort="Tingle, Aubrey J" uniqKey="Tingle A" first="Aubrey J" last="Tingle">Aubrey J. Tingle</name>
</author>
<author><name sortKey="Scheifele, David W" sort="Scheifele, David W" uniqKey="Scheifele D" first="David W" last="Scheifele">David W. Scheifele</name>
</author>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
</author>
<author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M" last="Patrick">David M. Patrick</name>
</author>
<author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G" last="Voss">Thomas G. Voss</name>
</author>
<author><name sortKey="Babiuk, Lorne A" sort="Babiuk, Lorne A" uniqKey="Babiuk L" first="Lorne A" last="Babiuk">Lorne A. Babiuk</name>
</author>
<author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name>
</author>
<author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L" last="Roper">Rachel L. Roper</name>
</author>
<author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C" last="Brunham">Robert C. Brunham</name>
</author>
<author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B Brett" last="Finlay">B Brett Finlay</name>
</author>
</analytic>
<series><title level="j">The Journal of general virology</title>
<idno type="ISSN">0022-1317</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibody Specificity</term>
<term>Disease Models, Animal</term>
<term>Drug Evaluation, Preclinical</term>
<term>Female</term>
<term>Immunoglobulin A (blood)</term>
<term>Immunoglobulin A (immunology)</term>
<term>Injections, Intramuscular</term>
<term>Injections, Subcutaneous</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>Neutralization Tests</term>
<term>Nucleocapsid Proteins (genetics)</term>
<term>SARS Virus (chemistry)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccination</term>
<term>Vaccines, DNA (administration & dosage)</term>
<term>Vaccines, DNA (genetics)</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Immunoglobuline A (immunologie)</term>
<term>Immunoglobuline A (sang)</term>
<term>Injections musculaires</term>
<term>Injections sous-cutanées</term>
<term>Modèles animaux de maladie humaine</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Protéines nucléocapside (génétique)</term>
<term>Souris</term>
<term>Spécificité des anticorps</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Tests de neutralisation</term>
<term>Vaccination</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins à ADN (administration et posologie)</term>
<term>Vaccins à ADN (génétique)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (immunologie)</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, DNA</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Nucleocapsid Proteins</term>
<term>Vaccines, DNA</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin A</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
<term>Vaccins à ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Protéines nucléocapside</term>
<term>Vaccins à ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Glycoprotéines membranaires</term>
<term>Immunoglobuline A</term>
<term>Protéines de l'enveloppe virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline A</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibody Specificity</term>
<term>Disease Models, Animal</term>
<term>Drug Evaluation, Preclinical</term>
<term>Female</term>
<term>Injections, Intramuscular</term>
<term>Injections, Subcutaneous</term>
<term>Mice</term>
<term>Neutralization Tests</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Injections musculaires</term>
<term>Injections sous-cutanées</term>
<term>Modèles animaux de maladie humaine</term>
<term>Souris</term>
<term>Spécificité des anticorps</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Tests de neutralisation</term>
<term>Vaccination</term>
<term>Virus du SRAS</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001378 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001378 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:16476986 |texte= Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:16476986" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |